On Tuesday, Fulcrum Therapeutics Inc (NASDAQ: FULC) opened higher 1.78% from the last session, before settling in for the closing price of $9.01. Price fluctuations for FULC have ranged from $3.14 to $13.70 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -1.10% over the last five years. Company’s average yearly earnings per share was noted 76.19% at the time writing. With a float of $58.02 million, this company’s outstanding shares have now reached $61.92 million.
The firm has a total of 76 workers. Let’s measure their productivity.
Fulcrum Therapeutics Inc (FULC) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Fulcrum Therapeutics Inc is 7.02%, while institutional ownership is 92.07%. The most recent insider transaction that took place on May 07 ’24, was worth 1,831. In this transaction Principal Accounting Officer of this company sold 236 shares at a rate of $7.76, taking the stock ownership to the 11,571 shares. Before that another transaction happened on Mar 08 ’24, when Company’s Vice President, Finance sold 4,884 for $11.72, making the entire transaction worth $57,219. This insider now owns 11,807 shares in total.
Fulcrum Therapeutics Inc (FULC) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 76.19% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.40% during the next five years compared to 1.09% growth over the previous five years of trading.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Trading Performance Indicators
Check out the current performance indicators for Fulcrum Therapeutics Inc (FULC). In the past quarter, the stock posted a quick ratio of 22.07. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.35, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.46 in one year’s time.
Technical Analysis of Fulcrum Therapeutics Inc (FULC)
Analysing the last 5-days average volume posted by the [Fulcrum Therapeutics Inc, FULC], we can find that recorded value of 0.66 million was lower than the volume posted last year of 0.72 million. As of the previous 9 days, the stock’s Stochastic %D was 51.43%. Additionally, its Average True Range was 0.71.
During the past 100 days, Fulcrum Therapeutics Inc’s (FULC) raw stochastic average was set at 79.14%, which indicates a significant increase from 60.99% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 90.17% in the past 14 days, which was higher than the 65.15% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.79, while its 200-day Moving Average is $7.42. Now, the first resistance to watch is $9.42. This is followed by the second major resistance level at $9.66. The third major resistance level sits at $9.87. If the price goes on to break the first support level at $8.97, it is likely to go to the next support level at $8.76. Should the price break the second support level, the third support level stands at $8.52.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Key Stats
There are currently 62,154K shares outstanding in the company with a market cap of 572.21 million. Presently, the company’s annual sales total 2,810 K according to its annual income of -97,340 K. Last quarter, the company’s sales amounted to 80,000 K and its income totaled 55,410 K.
